ASIT Biotech - The 82-centre gp-ASIT+ Phase III study launches
In a well-received announcement, ASIT has launched the confirmatory Phase III study on gp-ASIT+ for grass pollen allergy with study centres in six European countries. The results of the study are expected in December 2019. ASIT has learned from the previous Phase III study by making a number of improvements to the protocol to enhance the chances of success. In addition, ASIT has made announcements on its other products illustrating its pipeline in allergy extends beyond gp-ASIT+.Asit Biotech SA. Asit Biotech SA, formerly Biotech Tools SA, is a Belgium- based company that develops products aimed to prevent negative response of the immune system.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.